Jpmorgan Chase & CO Akouos, Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.6 - $5.16 $99,463 - $197,395	-38,255 Reduced 18.85%	164,649 $1.11 Million
Q2 2022 Aug 11, 2022	SELL	$2.46 - $5.2 $34,317 - $72,540	-13,950 Reduced 6.43%	202,904 $952,000
Q1 2022 May 11, 2022	BUY	$4.16 - $9.08 $207,975 - $453,945	49,994 Added 29.96%	216,854 $1.03 Million
Q4 2021 Feb 10, 2022	SELL	$7.65 - $11.38 $722,282 - $1.07 Million	-94,416 Reduced 36.14%	166,860 $1.42 Million
Q3 2021 Nov 12, 2021	BUY	$9.93 - $13.59 $2.59 Million - $3.55 Million	261,276 New	261,276 $3.03 Million

Ticker AKUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,929,000
Description
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therap...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.